Salvage boron neutron capture therapy for malignant brain tumor patients in compliance with emergency and compassionate use: Evaluation of 34 cases in Taiwan

Yi Wei Chen, Yi Yen Lee, Chun Fu Lin, Po Shen Pan, Jen Kun Chen, Chun Wei Wang, Shih Ming Hsu, Yu Cheng Kuo, Tien Li Lan, Sanford P.C. Hsu, Muh Lii Liang, Robert Hsin Hung Chen, Feng Chi Chang, Chih Chun Wu, Shih Chieh Lin, Hsiang Kuang Liang, Jia Cheng Lee, Shih Kuan Chen, Hong Ming Liu, Jinn Jer PeirKo Han Lin, Wen Sheng Huang, Kuan Hsuan Chen, Yu Mei Kang, Shueh Chun Liou, Chun Chieh Wang, Ping Ching Pai, Chih Wei Li, Daniel Quah Song Chiek, Tai Tong Wong, Shih Hwa Chiou, Yee Chao, Hiroki Tanaka, Fong In Chou, Koji Ono

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Although boron neutron capture therapy (BNCT) is a promising treatment option for malignant brain tumors, the optimal BNCT parameters for patients with immediately life-threatening, end-stage brain tumors remain unclear. We performed BNCT on 34 patients with life-threatening, end-stage brain tumors and analyzed the relationship between survival outcomes and BNCT parameters. Before BNCT, MRI and18F-BPA-PET analyses were conducted to identify the tumor location/distribution and the tumor-to-normal tissue uptake ratio (T/N ratio) of18F-BPA. No severe adverse events were observed (grade ≥ 3). The objective response rate and disease control rate were 50.0% and 85.3%, respectively. The mean overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS) times were 7.25, 7.80, and 4.18 months, respectively. Remarkably, the mean OS, CSS, and RFS of patients who achieved a complete response were 17.66, 22.5, and 7.50 months, respectively. Kaplan–Meier analysis identified the optimal BNCT parameters and tumor characteristics of these patients, including a T/N ratio ≥ 4, tumor volume < 20 mL, mean tumor dose ≥ 25 Gy-E, MIB-1 ≤ 40, and a lower recursive partitioning analysis (RPA) class. In conclusion, for malignant brain tumor patients who have exhausted all available treatment options and who are in an immediately life-threatening condition, BNCT may be considered as a therapeutic approach to prolong survival.

Original languageEnglish
Article number334
JournalBiology
Volume10
Issue number4
DOIs
Publication statusPublished - 2021

Keywords

  • BNCT
  • Glioblastoma
  • Radioresistance
  • T/B ratio
  • T/N ratio

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Agricultural and Biological Sciences(all)

Fingerprint

Dive into the research topics of 'Salvage boron neutron capture therapy for malignant brain tumor patients in compliance with emergency and compassionate use: Evaluation of 34 cases in Taiwan'. Together they form a unique fingerprint.

Cite this